版本:
中国

BRIEF-Basilea Pharmaceutica: agreement with FDA regarding ceftobiprole

April 21 Basilea Pharmaceutica AG:

* Basilea announces agreement with FDA on special protocol assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections

* Initiation of ceftobiprole pivotal phase 3 clinical program under barda contract anticipated within next three to six months Source text for Eikon: Further company coverage: (Gdynia Newsroom)

我们的标准: 汤森路透“信任原则

更多 瑞士市场报道

热门文章

编辑推荐

文章推荐